Articles tagged with Rheumatoid Arthritis
Scientists from Trinity College Dublin discovered that Interleukin-37 activates the immune system, contrary to earlier theories. This finding has significant implications for understanding and treating autoimmune disorders and inflammation.
People with rheumatoid arthritis have a higher risk of cardiovascular disease due to inflammation. However, new research suggests that commonly used treatments for RA can also lower this risk by reducing arterial inflammation and disease activity. The study found that immunomodulators like methotrexate and TNFi drugs reduced heart dise...
Exposure to common workplace agents is associated with a heightened risk of developing rheumatoid arthritis, which can be exacerbated by smoking and genetic predisposition. The study found that certain agents, such as quartz dust and gasoline fumes, are strongly linked to an increased risk of ACPA-positive disease.
A randomized clinical trial found that two anti-inflammatory strategies reduced disease activity and arterial inflammation in patients with moderate to high rheumatoid arthritis. The treatments had no differences in cardiovascular risk reduction, highlighting the importance of specific clinical trials for this population.
Researchers at Scripps Research developed nanoparticles that target only the immune cells driving an autoimmune reaction, delaying or preventing severe disease in a mouse model of arthritis. The treatment boosts regulatory T cell populations and reduces anti-self-antigen antibody production.
Gene variants associated with leukaemia produce 'rogue' killer T cells that drive autoimmune diseases, according to a new study. These rogue cells can cause autoimmune disease even at low levels, highlighting the connection between leukaemia and autoimmunity.
A study by King's College London found that the number of new diagnoses of rheumatoid arthritis fell by 20% during the COVID-19 pandemic, indicating a potential substantial burden of undiagnosed patients. In contrast, for those diagnosed during the pandemic, there were no delays in starting treatment.
A unique bacterium found in the gut microbiome may trigger an autoimmune response that leads to rheumatoid arthritis (RA) in individuals already at risk. The discovery opens up possibilities for targeted therapies and prevention strategies.
Researchers identified specific transcription factors involved in RA's heterogeneity and stratified cell lines into subtypes with distinct predicted activated pathways. This could help pave the way for personalized treatments tailored to individual patients' needs.
A new strategy for treating rheumatoid arthritis has been proposed, integrating small interfering RNAs and Prussian blue nanoparticles to silence proinflammatory cytokines and scavenge reactive oxygen species. The approach was tested in a mouse model, showing improved therapeutic efficacy and real-time monitoring capabilities.
A recent analysis found that individuals at risk for rheumatoid arthritis and those with the disease have higher blood levels of antibodies against Prevotella copri, a bacterial strain typically found in the gut. This study suggests that targeted therapies may be developed to prevent or treat the disease.
Researchers successfully visualized systemic joint involvement in patients with autoimmune arthritis using ultra-low dose total body PET/CT scans. The scans showed high agreement with standard joint-by-joint rheumatological evaluations and a moderate to strong correlation with rheumatological outcome measures.
A study found that aberrant expression of MAO-B causes both peripheral and neuroinflammation in RA patients, leading to joint pain and cognitive impairment. Administering an MAO-B inhibitor called KDS2010 improved both joint inflammation and cognitive function in a RA animal model.
Researchers at National Jewish Health found pirfenidone effective in slowing ILD progression in RA patients, potentially increasing overall survival. The study was the first prospective treatment trial for this condition.
A randomized clinical trial found that rituximab significantly improved disease control in patients with new-onset myasthenia gravis, reducing the need for cortisone treatments and hospitalizations. The study's results offer hope for a more effective treatment strategy, but larger studies are needed to assess long-term effects.
A new study published in the Journal of the American Heart Association found that individuals with autoimmune diseases are at a higher risk of complications after a heart attack. The research emphasizes the importance of controlling cardiovascular disease risk factors and developing personalized treatment plans for this population.
A study at Washington State University has identified sulfatase-2 as a critical protein driving damage caused by rheumatoid arthritis. The discovery sheds light on molecular processes behind inflammation in the disease and could lead to improved treatments.
A new drug has proven effective in treating rheumatoid arthritis, with results at least as good as the current 'gold standard' treatment. The medication targets a specific messenger molecule involved in inflammation and joint damage, offering a new approach to managing autoimmune disease.
Researchers at Michigan Medicine have discovered a molecular mechanism that drives the disease-causing effects of the most common genetic risk factor for lupus. The study suggests that targeting this new pathway could lead to the development of safe and effective treatments for SLE, an autoimmune disease that affects millions worldwide.
Researchers from the Journal of Internal Medicine outline a strategy for analyzing traditional Chinese medicine's effectiveness against rheumatoid arthritis. The approach involves isolating active components of individual plants and testing them in animal models of the disease.
Women with active rheumatic disease are at risk of hypertension, preeclampsia, and fetal loss during pregnancy. Effective disease management with safe medications is crucial for a successful pregnancy outcome.
Researchers at Karolinska Institutet discovered that electrical stimulation of the vagus nerve promotes healing in acute inflammation by shifting the balance between inflammatory and anti-inflammatory molecules. This finding opens new avenues for treating inflammatory diseases, including autoimmune and cardiovascular conditions.
Researchers from Arizona State University investigate autoantibodies in healthy individuals, revealing their pervasiveness and role in human health and disease. The findings aim to improve diagnostics and therapeutics for a range of illnesses.
A review of scientific evidence concludes that diet has little impact on the progression of osteoarthritis and rheumatoid arthritis. While a healthy diet brings other health benefits, the impact on these diseases is small and not clinically meaningful.
The Mount Sinai Microbiome Lab will use advanced methods to study the microbiome's role in autoimmune diseases such as rheumatoid arthritis and systemic lupus. The lab aims to identify microbial features that can help find more precise matches between diseases and treatments.
Researchers at Queen Mary University of London have identified genes that can predict response to arthritis treatment and paves the way for future drug development. The study found specific gene signatures associated with resistance to current therapies, which could lead to new treatments.
Researchers at Hokkaido University discovered that ATP secreted from sensory neuron-interneuron crosstalk triggers inflammation spread across joints, acting as a neurotransmitter and inflammation enhancer. Blocking this pathway prevents the spread of inflammation.
Researchers at Gwangju Institute of Science and Technology have developed a new bioinformatics pipeline, CRESSP, to investigate the mechanism underlying autoimmune diseases following SARS-CoV-2 infection. The tool identified potential epitopes responsible for COVID-related autoimmune diseases and predicted cross-reactive epitopes of di...
A neural network was trained to differentiate between healthy joints and those with rheumatoid or psoriatic arthritis using finger joint scans. The AI achieved high accuracy rates, detecting 82% of healthy joints, 75% of rheumatoid arthritis cases, and 68% of psoriatic arthritis cases.
Researchers have discovered sequence variants associated with a large increase in risk of seropositive rheumatoid arthritis. The study highlights the potential for repurposing drugs targeting key proteins involved in the JAK/STAT pathway.
A recent study suggests that many older adults with rheumatoid arthritis are not prescribed disease-modifying medications, despite guidelines calling for early and aggressive treatment. Only 45% of patients over 65 were prescribed these medications, highlighting the need to improve prescribing practices among primary care physicians.
Researchers analyzed genomic profiles of over one million cells from 1,000 people, identifying a link between specific genes and immune cell types in autoimmune diseases. The discovery could lead to tailored treatments and refine clinical trials.
A low-fat vegan diet has been shown to improve joint pain in patients with rheumatoid arthritis, as well as reduce inflammation. The study found that participants who followed a vegan diet experienced significant reductions in disease activity scores, swelling, and cholesterol levels.
Research published in RMD Open found a link between long-term exposure to traffic and industrial air pollutants and an increased risk of autoimmune diseases. Exposure to PM10 above 30 µg/m3 was associated with a 12% higher risk of autoimmune disease, while exposure to PM2.5 above 20 µg/m3 was associated with a 13% higher risk.
A new study predicts rheumatoid arthritis progression using a polygenic risk score. The score, generated from genetic variants associated with the disease, significantly differed between severe and non-severe progression groups. Higher scores were linked to higher risks of severe progression, particularly among younger patients.
A team of researchers at MedUni Vienna's Center for Physiology and Pharmacology has discovered a key building block in immune cells that promotes immunotolerance and prevents T-cell attacks on the body's own tissues. The study suggests a potential new cell-based therapeutic approach to slow down autoimmune disease progression.
Patients under immunosuppressive therapy have increased risk of severe COVID-19 disease courses if they don't respond to primary vaccination. A recent study found that a third booster vaccination is safe and effective in these patients, who were initially unable to produce antibodies after vaccination.
A new study found that disease-modifying antirheumatic drugs do not protect people with rheumatoid arthritis from developing Parkinson's disease. However, using chloroquine or hydroxychloroquine was associated with a lower risk of PD. The study controlled for various factors, including comorbidities and age.
A large-scale review of anti-inflammatory drugs used for autoimmune disorders suggests that current treatments can worsen lipid metabolism, leading to increased cardiovascular disease risk. Researchers propose the development of combination therapies targeting lipid metabolism to reduce immune complications and CVD risk in patients.
A registry study found that people with inflammatory RMDs, such as rheumatoid arthritis and psoriatic arthritis, tolerate their COVID vaccine well, with short-lived reactions being the most common side effect. The majority of participants were able to continue on their normal medication with no changes.
A study published in JAMA Internal Medicine found that people with immune dysfunction, such as HIV infection or rheumatoid arthritis, had a higher rate of COVID-19 breakthrough infections after vaccination. These individuals also experienced worse outcomes compared to those without immune dysfunction.
A study published in Annals of the Rheumatic Diseases found that crAss-like phages, a component of the gut virome, are less abundant in individuals with autoimmune diseases. This discovery may lead to the development of targeted therapies to manage autoimmune conditions.
Researchers at UC Riverside have discovered that targeting the TNFR1 receptor may be a more effective approach to treating inflammatory bowel disease. By selectively blocking TNFR1, they found significant benefits in mice with Crohn's-like ileitis, suggesting this approach could offer a new opportunity for healing.
Researchers used AI and genomic data to predict which patients with early-stage rheumatoid arthritis are most likely to benefit from methotrexate treatment within the first three months. The study identified potential personalized medicine approaches for rheumatoid arthritis treatment, paving the way for further research.
Researchers identified epimutations in cheek cells that can predict rheumatoid arthritis susceptibility. The discovery could lead to a non-invasive diagnostic test for the disease. Biomarkers were found in both Caucasian and African-American women with rheumatoid arthritis, suggesting a strong signal for the disease.
Researchers have linked T cell dysfunction in rheumatoid arthritis to a metabolic deficiency, suggesting a new therapeutic strategy. The study found that supplying the amino acid aspartate may provide a solution by repairing mitochondrial defects and suppressing TNF production.
People taking immunosuppressants, especially TNF inhibitors, have a weaker antibody response to COVID-19 vaccines. A third dose can drive antibody levels back up, but the duration is unknown.
A new study by Boston Children's Hospital researchers found that tissue-resident memory T cells in joints anchor themselves after a flare and wait for another trigger to react. Deleting these cells prevents arthritis flares from occurring, opening up new therapeutic avenues for rheumatoid arthritis treatment.
Researchers at University of Virginia Health System have discovered a new treatment target for osteoporosis and bone loss from rheumatoid arthritis. A cellular protein called ELMO1 promotes the activity of osteoclasts, which break down bone, leading to excessive bone degradation.
Researchers at UToledo have developed a protein-based vaccine that promotes a strong immune response, effectively treating rheumatoid arthritis and improving bone quality. The findings suggest long-term benefits following immunization.
A team of international researchers has unraveled the inner workings of C5aR2, a key receptor involved in inflammation and COVID-19. The study provides an additional opportunity for therapeutic targeting with new drug molecules to block its activation and inflammation response.
A new center will be established at CU Anschutz Medical Campus to investigate rheumatoid arthritis and spondyloarthritis, with the goal of identifying new treatments and preventing disease. The center will combine resources from over 40 researchers and provide funding for graduate students and postdoctoral fellows.
Researchers at Queen Mary University of London have created an experimental model of cardiomyopathy in inflammatory arthritis, replicating symptoms in RA patients. The study identifies a potential therapeutic approach to treat cardiomyopathy in RA patients.
A new study examines the similarities and differences among disease activity indices used to monitor rheumatoid arthritis. Researchers found that while there are high correlations among the indices, they were not interchangeable, highlighting the need for further analysis of RA in patients using various indices.
Researchers have genetically engineered cells that can deliver a biologic drug in response to inflammation, reducing inflammation and preventing bone damage in mice with rheumatoid arthritis. This approach could provide personalized treatments for arthritis patients, limiting side effects associated with current therapies.
A study found that hospitalized COVID-19 patients who received the rheumatoid arthritis drug baricitinib, in combination with the standard of care, died less often than those receiving only the standard of care. The COV-BARRIER trial showed a 5% reduction in 28-day and 60-day mortality.
Researchers at Washington University School of Medicine found that COVID-19 vaccination elicited a response in nearly nine out of ten people with weakened immune systems. However, the responses were only about one-third as strong as those mounted by healthy people. Despite this, the discovery is encouraging news for a population at hig...
A new study found that parental smoking may increase the risk of developing rheumatoid arthritis in children when they reach adulthood. The research, published in Arthritis & Rheumatology, associated parental smoking with a 75% higher risk of developing the disease, even after controlling for personal smoking habits as an adult.
Researchers found that some medications used to treat autoimmune rheumatic diseases can weaken the immune response to COVID-19 vaccines. Vaccination still induced an immune response in patients, but at a lower rate than in those without autoimmune diseases.
Researchers found that combining anti-rheumatic drugs can reduce the risk of cardiovascular disease in rheumatoid arthritis patients. Two specific combinations - tumour necrosis factor inhibitors and hydroxychloroquine - showed promise in preserving endothelial function.